

# Richard Fedorak

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5928115/richard-fedorak-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

250  
papers

23,240  
citations

70  
h-index

149  
g-index

251  
ext. papers

25,994  
ext. citations

6.4  
avg, IF

6.33  
L-index

#	Paper	IF	Citations
250	Pregnancy-Related Beliefs and Concerns of Inflammatory Bowel Disease Patients Modified After Accessing e-Health Portal. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2021</b> , 4, 27-35	0.5	4
249	Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2354-2372	4	14
248	Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 1909-1916	4.5	11
247	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 321, 773-783	27.4	75
246	The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta. <i>PharmacoEconomics - Open</i> , <b>2019</b> , 3, 591-597	2.1	0
245	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. <i>Frontiers in Medicine</i> , <b>2019</b> , 6, 170	4.9	5
244	Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1515-1524.e4	6.9	12
243	A BACH2 Gene Variant Is Associated with Postoperative Recurrence of Crohn's Disease. <i>Journal of the American College of Surgeons</i> , <b>2018</b> , 226, 902-908	4.4	3
242	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1578-1596	6.1	19
241	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1407-1419.e22	6.9	29
240	A Distinctive Urinary Metabolomic Fingerprint Is Linked With Endoscopic Postoperative Disease Recurrence in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 861-870	4.5	13
239	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 637-647.e13	6.9	27
238	Innovative Online Educational Portal Improves Disease-Specific Reproductive Knowledge Among Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 2483-2493	4.5	9
237	Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patients with Crohn's Disease. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	42
236	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2018</b> , 1, 115-123	0.5	21
235	Endospore forming bacteria may be associated with maintenance of surgically-induced remission in Crohn's disease. <i>Scientific Reports</i> , <b>2018</b> , 8, 9734	4.9	7
234	Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. <i>Gut</i> , <b>2017</b> , 66, 863-871	19.2	160

233	Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1232-1243	6.1	101
232	Biosimilars in the Treatment of Inflammatory Bowel Disease <b>2017</b> , 471-479		
231	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , <b>2017</b> , 7, e016146	3	26
230	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 833-839	4.5	59
229	Clinical validation of a novel urine-based metabolomic test for the detection of colonic polyps on Chinese population. <i>International Journal of Colorectal Disease</i> , <b>2017</b> , 32, 741-743	3	11
228	Development and Validation of a High-Throughput Mass Spectrometry Based Urine Metabolomic Test for the Detection of Colonic Adenomatous Polyps. <i>Metabolites</i> , <b>2017</b> , 7,	5.6	21
227	Prebiotic Supplementation Following Ileocecal Resection in a Murine Model is Associated With a Loss of Microbial Diversity and Increased Inflammation. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 24, 101-110	4.5	8
226	The NOD2-Smoking Interaction in Crohn's Disease is likely Specific to the 1007fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. <i>EBioMedicine</i> , <b>2017</b> , 21, 188-196	8.8	13
225	Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer. <i>Molecular and Clinical Oncology</i> , <b>2017</b> , 7, 767-770	1.6	13
224	Ileocolic resection is associated with increased susceptibility to injury in a murine model of colitis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0184660	3.7	2
223	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. <i>World Journal of Gastroenterology</i> , <b>2017</b> , 23, 3890-3899	5.6	16
222	Urine-based metabolomic analysis of patients with Clostridium difficile infection: a pilot study. <i>Metabolomics</i> , <b>2016</b> , 12, 1	4.7	6
221	Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 870-9	4.5	48
220	Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis. <i>Gastroenterology</i> , <b>2016</b> , 150, e1-2	13.3	4
219	Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. <i>Digestive Diseases</i> , <b>2016</b> , 34, 112-21	3.2	6
218	A 29-year-old woman with Crohn disease considering pregnancy. <i>Cmaj</i> , <b>2016</b> , 188, 131-132	3.5	
217	Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 2016, 5315798	2.8	6
216	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 2016, 2079582	2.8	12

215	Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 92-9	4.5	18
214	Ulcerative Colitis Patients With <i>Clostridium difficile</i> are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 691-704	0.7	45
213	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. <i>Digestive Diseases and Sciences</i> , <b>2016</b> , 61, 1895-902	4	7
212	The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 320-8	13.4	141
211	Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. <i>Gastroenterology</i> , <b>2015</b> , 148, 1035-1058.e3	13.3	251
210	The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 928-35.e2	6.9	134
209	Patients with Active Luminal Crohn's Disease Have Evidence of Significant Functional and Clinical Pulmonary Involvement. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 1817-24	4.5	3
208	Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. <i>Journal of Clinical Gastroenterology</i> , <b>2015</b> , 49, 675-82	3	27
207	Metagenomic analysis of microbiome in colon tissue from subjects with inflammatory bowel diseases reveals interplay of viruses and bacteria. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 1419-27	4.5	74
206	Randomised clinical trial: vécirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1170-81	6.1	59
205	Fecal Microbial Transplant After Ileocolic Resection Reduces Ileitis but Restores Colitis in IL-10 <sup>-/-</sup> Mice. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 1479-90	4.5	10
204	Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. <i>Inflammatory Bowel Diseases</i> , <b>2015</b> , 21, 1359-67	4.5	12
203	Clinicians' Guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 29, 369-72	2.8	44
202	Inflammatory bowel disease patients are frequently nonadherent to scheduled induction and maintenance infliximab therapy: A Canadian cohort study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2015</b> , 29, 309-14	2.8	10
201	Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. <i>Gastroenterology</i> , <b>2015</b> , 148, 1311-9.e6	13.3	140
200	Don't Forget the Doctor: Gastroenterologists' Preferences on the Development of mHealth Tools for Inflammatory Bowel Disease. <i>JMIR MHealth and UHealth</i> , <b>2015</b> , 3, e5	5.5	13
199	TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 10358-66	5.6	14
198	Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders. <i>World Journal of Gastrointestinal Pathophysiology</i> , <b>2015</b> , 6, 181-92	3.2	18

197	Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 1454-63	1.5	37
196	HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , <b>2014</b> , 46, 1131-4	36.3	130
195	Phenotypic features of Crohn's disease associated with failure of medical treatment. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 434-42.e1	6.9	43
194	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis. <i>Journal of Crohns and Colitis</i> , <b>2014</b> , 8, 571-81	1.5	54
193	Murine ileocolic bowel resection with primary anastomosis. <i>Journal of Visualized Experiments</i> , <b>2014</b> , e52106	106	3
192	Urine-based test for detection of colonic polyps: the coming of age. <i>Colorectal Cancer</i> , <b>2014</b> , 3, 239-241	0.8	
191	Vitamin D improves inflammatory bowel disease outcomes: basic science and clinical review. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 4934-47	5.6	75
190	Development and validation of a highly sensitive urine-based test to identify patients with colonic adenomatous polyps. <i>Clinical and Translational Gastroenterology</i> , <b>2014</b> , 5, e54	4.2	27
189	Disease manifestations of Helicobacter pylori infection in Arctic Canada: using epidemiology to address community concerns. <i>BMJ Open</i> , <b>2014</b> , 4, e003689	3	19
188	Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 1044-55	6.1	32
187	The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 629-38	6.1	70
186	Molecular patterns in human ulcerative colitis and correlation with response to infliximab. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 2353-63	4.5	18
185	Su1396 Crohn's Disease Outpatients Treated With Adalimumab Have an Earlier Loss of Response and Requirement for Dose Intensification Compared to Infliximab. <i>Gastroenterology</i> , <b>2014</b> , 146, S-457-S-458	133	2
184	Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. <i>Gastroenterology</i> , <b>2014</b> , 146, 681-688.e1	13.3	237
183	Real-life treatment paradigms show infliximab is cost-effective for management of ulcerative colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 1871-8.e8	6.9	10
182	Distance management of inflammatory bowel disease: systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 829-42	5.6	55
181	Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy. <i>Journal of Crohns and Colitis</i> , <b>2013</b> , 7, e42-8	1.5	83
180	Adalimumab for orbital myositis in a patient with Crohn's disease who discontinued infliximab: a case report and review of the literature. <i>BMC Gastroenterology</i> , <b>2013</b> , 13, 59	3	27

179	Vedolizumab as induction and maintenance therapy for Crohn's disease. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 711-21	59.2	1328
178	Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 252-62	6.1	132
177	Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). <i>Gastrointestinal Endoscopy</i> , <b>2013</b> , 77, 624-30	5.2	40
176	Commentary: larazotide acetate - an exciting new development for coeliac patients? AuthorsPreply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 37, 496-7	6.1	1
175	Celiac disease in children with inflammatory bowel disease: a prospective cohort study. <i>American Journal of Gastroenterology</i> , <b>2013</b> , 108, 455-6	0.7	3
174	A machine-learned predictor of colonic polyps based on urinary metabolomics. <i>BioMed Research International</i> , <b>2013</b> , 2013, 303982	3	26
173	A randomised phase I study of etrolizumab (rhuMAb $\bar{\mu}$ ) in moderate to severe ulcerative colitis. <i>Gut</i> , <b>2013</b> , 62, 1122-30	19.2	108
172	Prevalence of Epstein-Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 1248-54	6.1	31
171	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2013</b> , 38, 447-59	6.1	84
170	Epithelial cell extrusion leads to breaches in the intestinal epithelium. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 912-21	4.5	18
169	Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 3347-51	5.6	24
168	Prospective Study of the Quality of Colonoscopies Performed by Primary Care Physicians: The Alberta Primary Care Endoscopy (APC-Endo) Study. <i>PLoS ONE</i> , <b>2013</b> , 8, e67017	3.7	7
167	Metabolomic profiles are gender, disease and time specific in the interleukin-10 gene-deficient mouse model of inflammatory bowel disease. <i>PLoS ONE</i> , <b>2013</b> , 8, e67654	3.7	12
166	Environment and the inflammatory bowel diseases. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2013</b> , 27, e18-24		83
165	Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients. <i>Inflammatory Bowel Diseases</i> , <b>2012</b> , 18, 34-40	4.5	74
164	Intravenous injection of endogenous microbial components abrogates DSS-induced colitis. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 345-54	4	6
163	Small bowel fibrosis and systemic inflammatory response after ileocolonic anastomosis in IL-10 null mice. <i>Journal of Surgical Research</i> , <b>2012</b> , 178, 147-54	2.5	6
162	Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. <i>Gastroenterology Clinics of North America</i> , <b>2012</b> , 41, 821-42	4.4	20

161	Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. <i>Gastroenterology</i> , <b>2012</b> , 143, 1461-9	13.3	39
160	Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. <i>Journal of Crohns and Colitis</i> , <b>2012</b> , 6, 207-14	14.5	50
159	Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. <i>Journal of Crohns and Colitis</i> , <b>2012</b> , 6, 267-75	1.5	99
158	Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. <i>Journal of Crohns and Colitis</i> , <b>2012</b> , 6, 777-86	1.5	10
157	The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. <i>International Journal of Colorectal Disease</i> , <b>2012</b> , 27, 1657-64	3	49
156	Patients with inflammatory bowel disease exhibit dysregulated responses to microbial DNA. <i>PLoS ONE</i> , <b>2012</b> , 7, e37932	3.7	30
155	Development and validation of an administrative case definition for inflammatory bowel diseases. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2012</b> , 26, 711-7		67
154	Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease. <i>Clinical and Translational Gastroenterology</i> , <b>2012</b> , 3, e19	4.2	35
153	World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 468-81	3	226
152	Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 5058-64	5.6	19
151	Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. <i>Gastrointestinal Endoscopy</i> , <b>2011</b> , 73, 1174-80	5.2	60
150	A Novel Highly Sensitive Test for Detecting Colon Cancer Using Spot Urine Metabolomics. <i>Gastroenterology</i> , <b>2011</b> , 140, S-40	13.3	2
149	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , <b>2011</b> , 60, 780-7	19.2	576
148	Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2011</b> , 25, 140-6		13
147	Health care resource use and costs in Crohn's disease before and after infliximab therapy. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2011</b> , 25, 497-502		22
146	Patients with IBD are exposed to high levels of ionizing radiation through CT scan diagnostic imaging: a five-year study. <i>Journal of Clinical Gastroenterology</i> , <b>2011</b> , 45, 34-9	3	91
145	Mind the gaps: confocal endomicroscopy showed increased density of small bowel epithelial gaps in inflammatory bowel disease. <i>Journal of Clinical Gastroenterology</i> , <b>2011</b> , 45, 240-5	3	47
144	Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity. <i>British Journal of Clinical Pharmacology</i> , <b>2011</b> , 72, 787-97	3.8	19

143	A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2011</b> , 34, 181-7	6.1	28
142	Neonatal exposure to fecal antigens reduces intestinal inflammation. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 899-906	4.5	5
141	Epithelial gaps in a rodent model of inflammatory bowel disease: a quantitative validation study. <i>Clinical and Translational Gastroenterology</i> , <b>2011</b> , 2, e3	4.2	6
140	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD <b>2011</b> , 123-150		2
139	Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 522-8	6.1	74
138	Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 32, 1129-34	6.1	74
137	An imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animal's first exposure to faecal bacteria and antigens. <i>Clinical and Experimental Immunology</i> , <b>2010</b> , 161, 187-96	6.2	17
136	A randomized trial of topical anesthesia comparing lidocaine versus lidocaine plus xylometazoline for unsedated transnasal upper gastrointestinal endoscopy. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2010</b> , 24, 317-21		14
135	Canadian Digestive Health Foundation Public Impact Series. Inflammatory bowel disease in Canada: Incidence, prevalence, and direct and indirect economic impact. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2010</b> , 24, 651-5		17
134	Tumor necrosis factor- $\alpha$ monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. <i>Gastroenterology Clinics of North America</i> , <b>2010</b> , 39, 543-57	4.4	33
133	Metabolomics and detection of colorectal cancer in humans: a systematic review. <i>Future Oncology</i> , <b>2010</b> , 6, 1395-406	3.6	81
132	Peptic ulcer bleeding outcomes adversely affected by end-stage renal disease. <i>Gastrointestinal Endoscopy</i> , <b>2010</b> , 71, 44-9	5.2	66
131	S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease. <i>Gastroenterology</i> , <b>2010</b> , 138, S-167-S-168	13.3	12
130	Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. <i>Clinical Gastroenterology and Hepatology</i> , <b>2010</b> , 8, 688-695.e2	6.9	126
129	Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1272-7	4	49
128	Naturally occurring glycoalkaloids in potatoes aggravate intestinal inflammation in two mouse models of inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 3078-85	4	22
127	Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 1209-18	4.5	62
126	Probiotics in the management of ulcerative colitis. <i>Gastroenterology and Hepatology</i> , <b>2010</b> , 6, 688-90	0.7	10



125	Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2009</b> , 23, 348-52		29
124	Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2009</b> , 23, 185-202		33
123	Does smoking reduce infliximab's effectiveness against Crohn's disease?. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2009</b> , 23, 121-5		12
122	Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study. <i>Gut</i> , <b>2009</b> , 58, 1354-62	19.2	42
121	Effect of Lactobacillus plantarum 299v treatment in an animal model of irritable bowel syndrome. <i>Microbial Ecology in Health and Disease</i> , <b>2009</b> , 21, 33-37		6
120	Bacterial overgrowth and inflammation of small intestine after carboxymethylcellulose ingestion in genetically susceptible mice. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 359-64	4.5	100
119	Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 760-8	4.5	96
118	Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1599-604	4.5	84
117	Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile. <i>Journal of Proteome Research</i> , <b>2009</b> , 8, 5550-8	5.6	82
116	Probiotics in Ulcerative Colitis <b>2009</b> , 181-194		
115	A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. <i>Gastroenterology</i> , <b>2008</b> , 135, 1130-41	13.3	614
114	Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 465-71; quiz 371	6.9	24
113	Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 1370-7	6.9	236
112	Urinary metabolic profiles of inflammatory bowel disease in interleukin-10 gene-deficient mice. <i>Analytical Chemistry</i> , <b>2008</b> , 80, 5524-31	7.8	62
111	Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent?. <i>Journal of Medical Microbiology</i> , <b>2008</b> , 57, 111-117	3.2	23
110	Understanding why probiotic therapies can be effective in treating IBD. <i>Journal of Clinical Gastroenterology</i> , <b>2008</b> , 42 Suppl 3 Pt 1, S111-5	3	31
109	Recommendations for probiotic use--2008. <i>Journal of Clinical Gastroenterology</i> , <b>2008</b> , 42 Suppl 2, S104-83		99
108	Review and clinical perspectives for the use of infliximab in ulcerative colitis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2008</b> , 22, 261-72		7

107	Helicobacter pylori infection in Canada's arctic: searching for the solutions. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2008</b> , 22, 912-6		16
106	VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2008</b> , 22, 237-42		62
105	Exercise and inflammatory bowel disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2008</b> , 22, 497-504		54
104	Early experience with unsedated ultrathin 4.9 mm transnasal gastroscopy: a pilot study. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2008</b> , 22, 917-22		8
103	Canadian Digestive Health Foundation: Interview with the New President, Dr Richard Fedorak. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2008</b> , 22, 345-346		
102	Oropharyngeal Crohn's disease. <i>Clinical and Experimental Gastroenterology</i> , <b>2008</b> , 1, 15-8	3.1	6
101	CD4+CD25+ regulatory T cells have divergent effects on intestinal inflammation in IL-10 gene-deficient mice. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 1544-52		4
100	Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. <i>International Journal of Colorectal Disease</i> , <b>2008</b> , 23, 289-96	3	43
99	Vertebral fractures and role of low bone mineral density in Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2007</b> , 5, 721-8	6.9	41
98	Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. <i>Gastroenterology</i> , <b>2007</b> , 132, 1672-83	13.3	505
97	American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. <i>Gastroenterology</i> , <b>2007</b> , 133, 312-39	13.3	167
96	Epithelial barrier disruption allows nondisease-causing bacteria to initiate and sustain IBD in the IL-10 gene-deficient mouse. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 947-54	4.5	29
95	The role of probiotics in management of irritable bowel syndrome. <i>Current Gastroenterology Reports</i> , <b>2007</b> , 9, 393-400	5	13
94	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. <i>Gut</i> , <b>2007</b> , 56, 1232-9	19.2	715
93	Probiotics in the Management of Inflammatory Bowel Diseases?. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, S22-S28	0.7	3
92	Effects of probiotic therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. <i>American Journal of Clinical Nutrition</i> , <b>2007</b> , 85, 816-23	7	122
91	Probiotic Therapies for IBD. <i>Gastroenterology and Hepatology</i> , <b>2007</b> , 3, 180-1	0.7	
90	Probiotics in the Management of Inflammatory Bowel Diseases?. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 22-28	0.7	

89	The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , <b>2006</b> , 8, 486-98	5	37
88	The epidemiology of inflammatory bowel disease in Canada: a population-based study. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 1559-68	0.7	459
87	The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. <i>Journal of Medical Microbiology</i> , <b>2006</b> , 55, 1141-1149	3.2	194
86	Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. <i>Gastroenterology</i> , <b>2006</b> , 130, 323-33; quiz 591	13.3	1305
85	Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 888-93	6.9	58
84	Probiotics in the treatment of inflammatory bowel disease. <i>Journal of Clinical Gastroenterology</i> , <b>2006</b> , 40, 260-3	3	67
83	Recommendations for probiotic use. <i>Journal of Clinical Gastroenterology</i> , <b>2006</b> , 40, 275-8	3	49
82	Bacterial antigens alone can influence intestinal barrier integrity, but live bacteria are required for initiation of intestinal inflammation and injury. <i>Inflammatory Bowel Diseases</i> , <b>2006</b> , 12, 429-36	4.5	12
81	A defect in epithelial barrier integrity is not required for a systemic response to bacterial antigens or intestinal injury in T cell receptor-alpha gene-deficient mice. <i>Inflammatory Bowel Diseases</i> , <b>2006</b> , 12, 750-7	4.5	8
80	VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 1539-46	0.7	551
79	Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 122-32	6.9	70
78	Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 2499-507	59.2	633
77	The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. <i>Gastroenterology Clinics of North America</i> , <b>2005</b> , 34, 465-82, ix	4.4	38
76	Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. <i>Current Opinion in Pharmacology</i> , <b>2005</b> , 5, 596-603	5.1	96
75	A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. <i>Gastroenterology</i> , <b>2005</b> , 129, 807-18	13.3	491
74	Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. <i>Advanced Drug Delivery Reviews</i> , <b>2005</b> , 57, 303-16	18.5	71
73	Postoperative Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2005</b> , 11, 765-77	4.5	43
72	Association with selected bacteria does not cause enterocolitis in IL-10 gene-deficient mice despite a systemic immune response. <i>Digestive Diseases and Sciences</i> , <b>2005</b> , 50, 905-13	4	24

71	Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2005</b> , 19, 235-44		100
70	Probiotics in the management of inflammatory bowel disease. <i>MedGenMed: Medscape General Medicine</i> , <b>2005</b> , 7, 19		2
69	Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2004</b> , 18, 503-8		21
68	Endoscopic perforation rates at a Canadian university teaching hospital. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2004</b> , 18, 221-6		49
67	Infliximab maintenance therapy for fistulizing Crohn's disease. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 876-85	59.2	1727
66	Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2004</b> , 10, 220-8	4.5	62
65	Probiotics and the management of inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2004</b> , 10, 286-99	4.5	129
64	Is it time to re-classify Crohn's disease?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2004</b> , 18 Suppl, 99-106	2.5	9
63	Conservative approach to severe ulcerative colitis. <i>Digestive and Liver Disease</i> , <b>2004</b> , 36, 4-6	3.3	0
62	Probiotics and prebiotics in gastrointestinal disorders. <i>Current Opinion in Gastroenterology</i> , <b>2004</b> , 20, 146-55	3	90
61	The frequency of vitamin D deficiency in adults with Crohn's disease. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2003</b> , 17, 473-8		73
60	Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs. <i>Inflammatory Bowel Diseases</i> , <b>2003</b> , 9, 87-97	4.5	52
59	VSL3 probiotic mixture induces remission in patients with active ulcerative colitis. <i>Gastroenterology</i> , <b>2003</b> , 124, A377	13.3	19
58	Potato glycoalkaloids adversely affect intestinal permeability and aggravate inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , <b>2002</b> , 8, 340-6	4.5	52
57	Normal Breast Milk Limits the Development of Colitis in IL-10-Deficient Mice. <i>Inflammatory Bowel Diseases</i> , <b>2002</b> , 8, 390-8	4.5	24
56	A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1627-32	59.2	593
55	An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis (UC). <i>Gastroenterology</i> , <b>2000</b> , 118, A874	13.3	73
54	Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. <i>Gastroenterology</i> , <b>2000</b> , 119, 1461-72	13.3	376

53	Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. <i>Gastroenterology</i> , <b>2000</b> , 119, 1473-82	13.3	427
52	Antibiotic therapy attenuates colitis in interleukin 10 gene-deficient mice. <i>Gastroenterology</i> , <b>2000</b> , 118, 1094-105	13.3	194
51	Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1999</b> , 13, 1565-84	6.1	67
50	Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. <i>Gastroenterology</i> , <b>1999</b> , 116, 1107-14	13.3	636
49	Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. <i>Gastroenterology</i> , <b>1999</b> , 117, 527-35	13.3	195
48	Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. <i>Inflammatory Bowel Diseases</i> , <b>1999</b> , 5, 262-70	4.5	204
47	Endogenous interleukin-10 regulates hemodynamic parameters, leukocyte-endothelial cell interactions, and microvascular permeability during endotoxemia. <i>Circulation Research</i> , <b>1998</b> , 83, 1124-31	15.7	69
46	Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. <i>Gastroenterology</i> , <b>1997</b> , 113, 383-9	13.3	427
45	Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion. <i>Gastroenterology</i> , <b>1997</b> , 113, 151-9	13.3	141
44	A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. <i>Gastroenterology</i> , <b>1997</b> , 112, 1069-77	13.3	146
43	Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats. <i>Biopharmaceutics and Drug Disposition</i> , <b>1997</b> , 18, 681-95	1.7	6
42	Small intestinal function following syngeneic transplantation in the rat. <i>Journal of Surgical Research</i> , <b>1996</b> , 61, 379-84	2.5	28
41	Increased permeability occurs in rat ileum following induction of pan-colitis. <i>Digestive Diseases and Sciences</i> , <b>1996</b> , 41, 405-11	4	13
40	Nutritional and intestinal effects of the novel immunosuppressive agents: deoxyspergualin, rapamycin, and mycophenolate mofetil. <i>Clinical Biochemistry</i> , <b>1996</b> , 29, 363-9	3.5	15
39	Insulin downregulates diabetic-enhanced intestinal glucose transport rapidly in ileum and slowly in jejunum. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>1996</b> , 74, 1294-301	2.4	4
38	Tacrolimus (FK506)--its effects on intestinal glucose transport. <i>Transplantation</i> , <b>1996</b> , 61, 630-4	1.8	23
37	Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine. <i>Diabetologia</i> , <b>1995</b> , 38, 403-12	10.3	23
36	A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis. <i>American Journal of Physiology - Renal Physiology</i> , <b>1995</b> , 269, G210-8	5.1	

35	Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 292-7	59.2	782
34	Colonic delivery of dexamethasone from a prodrug accelerates healing of colitis in rats without adrenal suppression. <i>Gastroenterology</i> , <b>1995</b> , 108, 1688-99	13.3	35
33	FK506 increases permeability in rat intestine by inhibiting mitochondrial function. <i>Gastroenterology</i> , <b>1995</b> , 109, 107-14	13.3	67
32	The buried gastrostomy bumper syndrome: prevention and endoscopic approaches to removal. <i>Gastrointestinal Endoscopy</i> , <b>1995</b> , 41, 505-8	5.2	71
31	Budesonide-beta-D-glucuronide: a potential prodrug for treatment of ulcerative colitis. <i>Journal of Pharmaceutical Sciences</i> , <b>1995</b> , 84, 677-81	3.9	18
30	Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine. <i>Diabetologia</i> , <b>1995</b> , 38, 403-412	10.3	
29	A budesonide prodrug accelerates treatment of colitis in rats. <i>Gut</i> , <b>1994</b> , 35, 1439-46	19.2	40
28	Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. <i>New England Journal of Medicine</i> , <b>1994</b> , 330, 1846-51	59.2	222
27	Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. <i>Gastroenterology</i> , <b>1994</b> , 106, 287-96	13.3	601
26	A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. <i>Gastroenterology</i> , <b>1994</b> , 106, 405-13	13.3	32
25	Jejunum is preferable for construction of a Bianchi bowel-lengthening procedure in swine short bowel. <i>Journal of Pediatric Surgery</i> , <b>1993</b> , 28, 102-9	2.6	11
24	Oral vanadate reduces Na(+)-dependent glucose transport in rat small intestine. <i>Diabetes</i> , <b>1993</b> , 42, 1126-32	6.32	17
23	Acetic acid-induced colitis results in bystander ileal injury. <i>Agents and Actions</i> , <b>1993</b> , 38, 76-84		10
22	Intestinal function following allogeneic small intestinal transplantation in the rat. <i>Transplantation</i> , <b>1992</b> , 53, 264-71	1.8	36
21	Food consistency effects of quarg in lactose malabsorption. <i>International Dairy Journal</i> , <b>1992</b> , 2, 257-269	3.5	18
20	Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerates healing. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>1992</b> , 45, 275-81	2.8	9
19	Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in rats. <i>Digestive Diseases and Sciences</i> , <b>1992</b> , 37, 205-14	4	72
18	Verapamil alters eicosanoid synthesis and accelerates healing during experimental colitis in rats. <i>Gastroenterology</i> , <b>1992</b> , 102, 1229-35	13.3	7

17	Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in rats. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>1991</b> , 69, 480-7	2.4	46
16	Adaptation of intestinal glucose transport in rats with diabetes mellitus occurs independent of hyperphagia. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>1991</b> , 69, 1143-8	2.4	13
15	Diabetes mellitus and glucagon alter ouabain-sensitive Na(+)-K(+)-ATPase in rat small intestine. <i>Diabetes</i> , <b>1991</b> , 40, 1603-10	0.9	11
14	Altered glucose carrier expression: mechanism of intestinal adaptation during streptozocin-induced diabetes in rats. <i>American Journal of Physiology - Renal Physiology</i> , <b>1991</b> , 261, G585-591	5.1	34
13	Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. <i>Gastroenterology</i> , <b>1990</b> , 98, 615-25	13.3	131
12	The physiology of adaptation to small bowel resection in the pig: an integrated study of morphological and functional changes. <i>Journal of Pediatric Surgery</i> , <b>1990</b> , 25, 650-7	2.6	50
11	Effect of somatostatin analog (SMS 201-995) on in vivo intestinal fluid transport in rats. A limited systemic effect. <i>Digestive Diseases and Sciences</i> , <b>1989</b> , 34, 567-72	4	11
10	Effect of misoprostol in preventing stress-induced intestinal fluid secretion in rats. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , <b>1989</b> , 38, 43-8	2.8	15
9	Inhibition of cholera-toxin-stimulated intestinal secretion by CGS 9343B in rats: a specific calmodulin inhibitor. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>1989</b> , 8, 252-8	2.8	4
8	In vitro effects of the long-acting somatostatin analogue SMS 201-995 on electrolyte transport by the rabbit ileum. <i>Gastroenterology</i> , <b>1988</b> , 94, 1343-50	13.3	25
7	Antidiarrheal therapy. Prospects for new agents. <i>Digestive Diseases and Sciences</i> , <b>1987</b> , 32, 195-205	4	20
6	Intestinal adaptation to diabetes. Altered Na-dependent nutrient absorption in streptozocin-treated chronically diabetic rats. <i>Journal of Clinical Investigation</i> , <b>1987</b> , 79, 1571-8	15.9	49
5	Experimental diabetic diarrhea in rats. <i>Gastroenterology</i> , <b>1986</b> , 91, 564-569	13.3	56
4	Experimental diabetic diarrhea in rats. Intestinal mucosal denervation hypersensitivity and treatment with clonidine. <i>Gastroenterology</i> , <b>1986</b> , 91, 564-9	13.3	19
3	Treatment of diabetic diarrhea with clonidine. <i>Annals of Internal Medicine</i> , <b>1985</b> , 102, 197-9	8	142
2	Short Bowel Syndrome 1295-1321		
1	Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. <i>Inflammatory Bowel Diseases</i> , <b>2005</b> , 11, 262-270	4.5	27